Results 251 to 260 of about 143,942 (291)
The Association Between Obesity Indices and Non-Alcoholic Fatty Liver Disease in Patients with Ankylosing Spondylitis. [PDF]
Arch RheumatolKutluk O +4 more
europepmc +1 more source
Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway. [PDF]
Am J Transl ResWu P +9 more
europepmc +1 more source
The association between weight-adjusted waist index (WWI) and nonalcoholic fatty liver disease (NAFLD) in non-diabetic individuals: A study based on the NHANES database(2017-2023). [PDF]
Medicine (Baltimore)Zhu S +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2021
Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase
Bubu A, Banini, Arun J, Sanyal
openaire +2 more sources
Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase
Bubu A, Banini, Arun J, Sanyal
openaire +2 more sources
Digestive Diseases and Sciences, 2022
Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve this target at 1-year, and fewer maintain the weight loss at 5 years ...
Mahak Chauhan +2 more
openaire +2 more sources
Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve this target at 1-year, and fewer maintain the weight loss at 5 years ...
Mahak Chauhan +2 more
openaire +2 more sources